| Symbol | LRMR |
|---|---|
| Name | LARIMAR THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | THREE BALA PLAZA EAST,SUITE 506, BALA CYNWYD, Pennsylvania, 19004, United States |
| Telephone | +1 844 511-9056 |
| Fax | — |
| — | |
| Website | https://www.larimartx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001374690 |
| Description | Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreichs ataxia. Additional info from NASDAQ: |
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Read more(10% Negative) LARIMAR THERAPEUTICS, INC. (LRMR) Announces Delay in package Trials for multi-disciplinary Type B pre-BLA meeting minutes Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Read moreLarimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Read moreDirector Flynn James E 🟢 acquired 55.1K shares (1 derivative) of Larimar Therapeutics, Inc. (LRMR) at $3.33 Transaction Date: May 19, 2026 | Filing ID: 000669
Read moreLEFF JONATHAN S 🟢 acquired 55.1K shares (1 derivative) of Larimar Therapeutics, Inc. (LRMR) at $3.33 Transaction Date: May 19, 2026 | Filing ID: 232933
Read moreSHERMAN JEFFREY W 🟢 acquired 55.1K shares (1 derivative) of Larimar Therapeutics, Inc. (LRMR) at $3.33 Transaction Date: May 19, 2026 | Filing ID: 232705
Read moreTruitt Joseph 🟢 acquired 55.1K shares (1 derivative) of Larimar Therapeutics, Inc. (LRMR) at $3.33 Transaction Date: May 19, 2026 | Filing ID: 232667
Read moreTHOMAS FRANK E 🟢 acquired 55.1K shares (1 derivative) of Larimar Therapeutics, Inc. (LRMR) at $3.33 Transaction Date: May 19, 2026 | Filing ID: 232657
Read moreHamilton Thomas Edward 🟢 acquired 55.1K shares (1 derivative) of Larimar Therapeutics, Inc. (LRMR) at $3.33 Transaction Date: May 19, 2026 | Filing ID: 232644
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06681766 | A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ata… | Phase1 | Friedreich Ataxia | Terminated | 2024-12-06 | 2025-04-28 | ClinicalTrials.gov |
| NCT06447025 | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Phase2 | Friedreich Ataxia | Recruiting | 2024-01-25 | 2027-01-01 | ClinicalTrials.gov |
| NCT05579691 | A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult… | Phase2 | Friedreich Ataxia | Completed | 2022-09-21 | 2023-12-04 | ClinicalTrials.gov |
| NCT05028764 | Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers | — | Friedreich Ataxia | Completed | 2021-08-04 | 2022-02-04 | ClinicalTrials.gov |
| NCT04519567 | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Fried… | Phase1 | Friedreich Ataxia | Completed | 2020-07-31 | 2021-03-16 | ClinicalTrials.gov |
| NCT04255680 | A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia | — | Friedreich Ataxia | Completed | 2020-01-14 | 2020-06-30 | ClinicalTrials.gov |
| NCT04176991 | Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedre… | Phase1 | Friedreich Ataxia | Completed | 2019-12-11 | 2020-10-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| Buccal Swabs and Blood Draws | Other | Preclinical | Friedreich Ataxia | COMPLETED | NCT04255680 |
| Placebo | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04176991 |
| CTI-1601 | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04176991 |
| Placebo | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04519567 |
| CTI-1601 | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04519567 |
| Buccal Swabs, Blood Draws and Skin Punch Biopsy | Other | Preclinical | Friedreich Ataxia | COMPLETED | NCT05028764 |
| Placebo | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT05579691 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT05579691 |
| Placebo | Other | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| Nomlabofusp | Other | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| Nomlabofusp | DRUG | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| Placebo | DRUG | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| CTI-1601 | DRUG | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |